Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials
Crossref DOI link: https://doi.org/10.1007/s40121-018-0218-x
Published Online: 2018-10-27
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tran, Tram T.
Mehta, Darshan
Mensa, Federico
Park, Caroline
Bao, Yanjun
Sanchez Gonzalez, Yuri
Funding for this research was provided by:
AbbVie
Article History
Received: 21 August 2018
First Online: 27 October 2018